Status: Recruiting
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Nov 20, 2025Locations: 16
Eligibility criteria
Age ≥ 18 years [+18]
Have disease that is suitable for local therapy administered with curative inten... [+16]